Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

BACKGROUND: The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer (mUC) upon progression to platinum-based chemotherapy worldwide. Yet, the real impact of this drug in specific geographical regions is...

Descripción completa

Detalles Bibliográficos
Autores principales: Sotelo, M., Alonso-Gordoa, T., Gajate, P., Gallardo, E., Morales-Barrera, R., Pérez-Gracia, J. L., Puente, J., Sánchez, P., Castellano, D., Durán, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979625/
https://www.ncbi.nlm.nih.gov/pubmed/32897497
http://dx.doi.org/10.1007/s12094-020-02482-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979625/
https://www.ncbi.nlm.nih.gov/pubmed/32897497
http://dx.doi.org/10.1007/s12094-020-02482-9

Ejemplares similares